ES2574231T3 - Uso de liposomas catiónicos que comprenden paclitaxel - Google Patents

Uso de liposomas catiónicos que comprenden paclitaxel Download PDF

Info

Publication number
ES2574231T3
ES2574231T3 ES10180750.1T ES10180750T ES2574231T3 ES 2574231 T3 ES2574231 T3 ES 2574231T3 ES 10180750 T ES10180750 T ES 10180750T ES 2574231 T3 ES2574231 T3 ES 2574231T3
Authority
ES
Spain
Prior art keywords
mol
paclitaxel
cationic
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10180750.1T
Other languages
English (en)
Spanish (es)
Inventor
Michael Teifel
Uwe Michaelis
Birgitta Sauer
Kerstin Bartelheim
Christoph Brunner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syncore Biotechnology Co Ltd
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Application granted granted Critical
Publication of ES2574231T3 publication Critical patent/ES2574231T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
ES10180750.1T 2003-10-15 2004-10-15 Uso de liposomas catiónicos que comprenden paclitaxel Expired - Lifetime ES2574231T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03023539 2003-10-15
EP03023539 2003-10-15
EP04000361 2004-01-09
EP04000361 2004-01-09

Publications (1)

Publication Number Publication Date
ES2574231T3 true ES2574231T3 (es) 2016-06-16

Family

ID=34524705

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10180750.1T Expired - Lifetime ES2574231T3 (es) 2003-10-15 2004-10-15 Uso de liposomas catiónicos que comprenden paclitaxel

Country Status (11)

Country Link
US (1) US20080063699A1 (enExample)
EP (2) EP2286794B8 (enExample)
JP (2) JP5645340B2 (enExample)
AU (1) AU2004283464B8 (enExample)
CA (1) CA2542217C (enExample)
DK (1) DK2286794T3 (enExample)
ES (1) ES2574231T3 (enExample)
HU (1) HUE028648T2 (enExample)
PL (1) PL2286794T3 (enExample)
PT (1) PT2286794T (enExample)
WO (1) WO2005039533A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
CN101257891A (zh) * 2005-09-01 2008-09-03 比奥里波克斯公司 包含抗组胺剂以及皮质类固醇的脂质体组合物及其在制备治疗鼻炎以及相关疾病的药物中的用途
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
DE602007007618D1 (de) * 2006-05-18 2010-08-19 Univ Muenchen L Maximilians Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
AU2013212068B2 (en) 2012-01-26 2018-02-15 Life Technologies Corporation Methods for increasing the infectivity of viruses
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
KR102742522B1 (ko) 2015-09-16 2024-12-12 디에프비 소리아, 엘엘씨 약물 나노입자 전달체 및 이의 제조방법
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017176628A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
BR112019023948A2 (pt) 2017-06-09 2020-06-09 Crititech Inc tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
EP3615004B1 (en) 2017-06-14 2025-02-19 Crititech, Inc. Methods for treating lung disorders
JP7792750B2 (ja) 2017-10-03 2025-12-26 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
JP2026505783A (ja) * 2023-01-31 2026-02-18 石薬集団中奇制薬技術（石家庄）有限公司 腫瘍を治療するためのパクリタキセルカチオンリポソームの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
DE4430593C2 (de) * 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
HUP0202669A3 (en) * 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
JP2005534718A (ja) * 2002-06-26 2005-11-17 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend

Also Published As

Publication number Publication date
AU2004283464A1 (en) 2005-05-06
JP2007508353A (ja) 2007-04-05
EP2286794B8 (en) 2016-06-01
AU2004283464B8 (en) 2011-04-14
PL2286794T3 (pl) 2016-10-31
EP2286794B1 (en) 2016-03-30
EP2286794A1 (en) 2011-02-23
AU2004283464B2 (en) 2011-03-17
CA2542217A1 (en) 2005-05-06
WO2005039533A1 (en) 2005-05-06
EP1673069B1 (en) 2016-10-12
CA2542217C (en) 2018-03-27
JP2012229255A (ja) 2012-11-22
EP1673069A1 (en) 2006-06-28
US20080063699A1 (en) 2008-03-13
PT2286794T (pt) 2016-07-13
JP5645340B2 (ja) 2014-12-24
DK2286794T3 (en) 2016-07-25
HUE028648T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
ES2574231T3 (es) Uso de liposomas catiónicos que comprenden paclitaxel
US9827196B2 (en) Method of administering a cationic liposomal preparation
ES2609388T3 (es) Tratamiento del cáncer de mama triple negativo a receptores
US20230035723A1 (en) Treatment of Pancreatic Cancer
ES2902576T3 (es) Tratamiento de cáncer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional
HK1123229B (en) Treatment of triple receptor negative breast cancer